The emergence of new influenza virus strains presents a continuous challenge for global public health. mRNA technology offers a promising platform for rapidly developing therapeutics, particularly monoclonal antibodies, that can protect against viral infections. In this study, we engineered mRNA constructs encoding two types of antibodies: secreted antibodies specific to the hemagglutinin of the influenza A virus, based on previously characterized Fi6 antibodies, and intracellular Fab fragments targeting the nucleoprotein of the influenza B virus, derived from the 2/3 antibodies.
View Article and Find Full Text PDFIntroduction: Small membrane particles called extracellular vesicles (EVs) transport biologically active cargo between cells, providing intercellular communication. The clinical application of EVs is limited due to the lack of scalable and cost-effective approaches for their production and purification, as well as effective loading strategies.
Methods: Here we used EV mimetics produced by cell treatment with the actin-destabilizing agent cytochalasin B as an alternative to EVs for the delivery of therapeutic nucleic acids.
The development of polymer-lipid hybrid nanoparticles (PLNs) is a promising area of research, as it can help increase the stability of cationic lipid carriers. Hybrid PLNs are core-shell nanoparticle structures that combine the advantages of both polymer nanoparticles and liposomes, especially in terms of their physical stability and biocompatibility. Natural polymers such as polyhydroxyalkanoate (PHA) can be used as a matrix for the PLNs' preparation.
View Article and Find Full Text PDFThis work presents a system upgrade of the High Resolution Thomson Scattering (HRTS) diagnostic [Pasqualotto et al., Rev. Sci.
View Article and Find Full Text PDF